Quote | InMed Pharmaceuticals Inc. (NASDAQ:INM)
Last: | $0.2675 |
---|---|
Change Percent: | 2.98% |
Open: | $0.2568 |
Close: | $0.2675 |
High: | $0.2691 |
Low: | $0.256 |
Volume: | 317,824 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | InMed Pharmaceuticals Inc. (NASDAQ:INM)
InMed (NASDAQ: INM) is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Deg...
2024-06-28 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When does a growth stock become one of the top growth stocks to avoid? It sounds like the beginning of a riddle or a bad joke, but the answer is obvious – it’s when the st...
Message Board Posts | InMed Pharmaceuticals Inc. (NASDAQ:INM)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $INM 38% v22,1M c1.46 f3,328M H1.68 ML.92 | znewcar1 | investorshangout | 03/20/2023 10:43:43 PM |
NetworkNewsWire: NetworkNewsBreaks InMed Pharmaceuticals Inc. (NASDAQ: INM) Peer-Reviewed Study Res | NetworkNewsWire | investorshangout | 03/13/2023 8:57:12 PM |
NetworkNewsWire: NetworkNewsBreaks InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q2 2023 Financ | NetworkNewsWire | investorshangout | 02/21/2023 8:43:52 PM |
znewcar1: $INM 36% v4,4M c2.30 f1,589M H2.41 ML1.23 | znewcar1 | investorshangout | 01/10/2023 10:04:53 PM |
NetworkNewsWire: NetworkNewsBreaks InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestone | NetworkNewsWire | investorshangout | 01/10/2023 8:35:09 PM |
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed (NASDAQ: INM) is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company recently released several critical updates regarding its INM-089 therapy treating dry Age-related Macular Deg...
INM is advancing INM-089 targeting age-related macular degeneration and INM-901 targeting Alzheimer’s disease The company recently posted positive results for INM-089 demonstrating significant functional and pathological improvements in an AMD disease model Recent preclinical data for ...